Axsome Therapeutics Reports Strong Revenue Growth and Pipeline Progress
Axsome Therapeutics (NASDAQ:AXSM) reported strong second-quarter revenue of $218.4 million, driven primarily by its flagship product Auvelity, which contributed over $180 million in sales. The company highlighted the recent approval for a new Alzheimer's disease agitation indication and an expanded sales force exceeding 600 representatives to support this growth area. In addition to Auvelity’s success, Axsome noted sequential revenue increases from its other commercial products: Sunosi grew steadily with $36 million in Q2 revenue, while SYMBRAVO saw a 30% increase sequentially. The company also emphasized late-stage clinical programs and strong financials, ending the quarter with $320 million in cash and nearing cash-flow positivity. Axsome’s leadership expressed confidence in future growth as Auvelity's market access expands across Medicare Part D plans, offering unrestricted or first-line access to over 85% of patients. The company is positioned for continued expansion through its commercial portfolio and pipeline advancements.
Tickers: $AXSM
Topics: Auvelity Pipeline Progress Revenue Growth Sunosi SYMBRAVO